drugset
drugset / Trial / NCT02115542

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

NCT02115542 ↗

Phase 2 Completed 39 enrolled H. Lee Moffitt Cancer Center and Research Institute Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.

Timeline

Start
2014-06-05
Primary completion
2018-12-10
Completion
2021-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Regorafenib Small molecule 160 mg Oral

Indications

bile duct cancer